Professional Documents
Culture Documents
A complete electronic version of this article and other services, including high-resolution figures,
can be found at:
http://stm.sciencemag.org/content/4/165/165rv13.full.html
Supplementary Material can be found in the online version of this article at:
http://stm.sciencemag.org/content/suppl/2012/12/17/4.165.165rv13.DC1.html
Related Resources for this article can be found online at:
http://stm.sciencemag.org/content/scitransmed/2/15/15cm3.full.html
http://stm.sciencemag.org/content/scitransmed/3/69/69cm3.full.html
http://stm.sciencemag.org/content/scitransmed/4/149/149fs32.full.html
http://stm.sciencemag.org/content/scitransmed/3/69/69cm4.full.html
Science Translational Medicine (print ISSN 1946-6234; online ISSN 1946-6242) is published weekly, except the
last week in December, by the American Association for the Advancement of Science, 1200 New York Avenue
NW, Washington, DC 20005. Copyright 2012 by the American Association for the Advancement of Science; all
rights reserved. The title Science Translational Medicine is a registered trademark of AAAS.
REVIEW
MEDICAL MYCOLOGY
and modern immunosuppressive and invasive medical interventions. system, and most clinical cases present with meningoencephalitis (in-
For example, the vast majority of patients with cryptococcosis—for flammation of the brain and meninges) (Fig. 1).
which we have comparatively strong epidemiological data, at least Historically, C. gattii was found mainly in tropical and subtropical
from economically developed countries—have quantitative or qualita- regions of the world and affected people who were not immunocom-
tive defects in cellular immune function, specifically in CD4+ lympho- promised. However, since 1990, human and veterinary cases of C. gattii–
cytes. AIDS is the major risk factor, although individuals who have induced cryptococcosis have been reported with increasing frequency
received immunosuppressive medications, particularly in the setting on Vancouver Island, Canada (9), and this outbreak has since spread
of solid organ transplantation, are also predisposed. The CDC recently to mainland British Columbia and Washington and Oregon in the
estimated the yearly global burden of cryptococcal meningitis to be United States. Moreover, a second hypervirulent strain has emerged
nearly 1 million cases, with more than 620,000 deaths in sub-Saharan in Oregon (10). Although C. gattii has been isolated from samples
Africa (8). Mortality rates in AIDS patients are estimated to range of air, soil, and tree debris in outbreak regions, it has been difficult
from 15 to 20% in the United States and 55 to 70% in Latin America to link specific environmental sources to individual cases. For both
and sub-Saharan Africa, despite treatment (8). outbreaks, most of the patients had little to no underlying immuno-
Virtually all cases of cryptococcosis are caused by Cryptococcus deficiency, although one could envisage genetic variation affecting host
neoformans and the closely related species Cryptococcus gattii. C. neoformans defense as the cause of disease in a subgroup of the population. Al-
has a worldwide distribution, particularly in soil and avian habitats. though the numbers of afflicted have thus far been relatively small, the
allows an estimate (24) of the annual global incidence of Candida diseases, including asthma, and has an at least 15% mortality in the first
bloodstream infections at ~400,000 cases, with the most occurring 6 months after diagnosis (equating to at least 450,000 deaths world-
in economically developed regions of the world. Crude and attrib- wide), often as a result of massive pulmonary hemorrhage (30, 31).
utable mortality rates of 42 and 27%, respectively, are very high even A. fumigatus is also a ubiquitous aeroallergen. Globally, millions
in comparison to the most aggressive types of bacterial and viral of susceptible individuals develop pulmonary and nasal allergies to
sepsis (25). A. fumigatus and other airborne fungal particles. Severe asthma is linked
Continuous lung exposure to Aspergillus species translates into the to fungal allergy and A. fumigatus colonization (or infection) of the
common occurrence of invasive infections in individuals with im- airway, principally in adults, but also in children (32–34). Severe asthma
paired immune function, in particular those with lower than normal with fungal sensitization is thought to affect between 3.25 million and
numbers of neutrophils, solid organ transplant recipients, and patients 13 million adults worldwide and to contribute to the 100,000 people
on immunosuppressive therapies, such as high-dose corticosteroids. who die from asthma annually (29). Allergic bronchopulmonary as-
An emerging risk group includes patients with chronic obstructive pul- pergillosis is a discrete allergic syndrome estimated to affect more than
monary disease (COPD; also called emphysema). These opportunistic 4 million people with asthma and cystic fibrosis worldwide (35, 36),
infections are caused primarily by Aspergillus fumigatus and Aspergillus whereas allergic fungal rhinosinusitis affects ~1.3% of those with chronic
flavus, spore-producing species that are found worldwide and are com- rhinitis, ~12 million people (29).
mon in the environment. Another common respiratory opportunistic pathogen is Pneumo-
from clinical data gathered in the United States, where PCP occurs in Pneumocystis may also contribute to the deterioration of COPD
AIDS patients on antiretroviral therapy at a rate of 3 infections per and thus to the annual 3 million deaths globally that are attributed
100 person-years (41). With 1.2 million AIDS patients (42), we to this disease (46, 47).
estimate that there are ~36,000 cases of PCP each year in the United Fungi also contribute to several other notable diseases, including
States. The combined population of HIV-infected individuals in other infection-related blindness and the debilitating and disfiguring chronic
economically developed countries is three times the size of that in the subcutaneous infections. Fungal keratitides (infections of the cornea)
United States, suggesting that ~108,000 cases of PCP occur each year are notable for their frequency (~1 million new fungal eye infections
in the developed world. The population of HIV-infected people in the annually worldwide) and their contribution to blindness, particularly in
developing world is more than six times that of the economically de- Asia and Africa (48). The subcutaneous mycoses are generally uncommon
veloped countries; these individuals often do not have ready access to and include chromoblastomycosis (Fig. 1), sporotrichosis, Madura foot
antiretroviral drugs, which means that they continue to be immuno- (eumycetoma), and the fortunately rare entomophthoramycosis.
compromised and less able to fight Pneumocystis infections. In Africa,
for example, the number of AIDS-related deaths is estimated to be ~1.3
million each year. Because hospitalizations driven by Pneumocystis in- INFECTION AND IMMUNITY
fection are estimated to be 11% or higher in these patients, we calcu-
late that there are more than 143,000 new cases of PCP each year The increased prevalence of fungal infections has stimulated one branch of
Fig. 2. Host defense mechanisms. In the human host, fungal infections TH2 and some other regulatory T lymphocytes (under the control of
are fought by both humoral (complement, antibodies) and cellular (phago- modulatory mechanisms such as indoleamine 2,3-dioxygenase) release
cytes, T cells) immune mechanisms. Protective mechanisms in both sys- anti-inflammatory cytokines that provide the tolerance mechanisms necessary
temic and mucosal antifungal immunity are based on chemotaxis and to balance inflammation and tissue damage. However, when activated inap-
activation of neutrophils, monocytes/macrophages, and, in the case of propriately or too strongly, the anti-inflammatory TH2 and other regulatory T
mucosal immunity, epithelial cells, by chemokines and cytokines released cell responses can down-regulate antifungal immunity and increase suscepti-
by macrophages and proinflammatory TH1 and TH17 cells. In contrast, bility to infection. CREDIT: C. BICKEL/SCIENCE TRANSLATIONAL MEDICINE
human host (Fig. 2). One prominent breakthrough was an appreciation of immunity, particularly to invasive infections with Aspergillus, Candi-
the importance of innate-immune Toll-like receptors (TLRs) in an- da, and Cryptococcus, there remains much to be learned. For example,
timicrobial host defense. TLRs were originally identified in fruit flies as there are still no antifungal vaccines, and we know little about the
essential components for the development of resistance to infection with immunopathological processes of the common noninvasive fungal in-
Aspergillus (and later, other fungi). The discovery of TLRs as key players in fections, such as recurrent vulvovaginal candidiasis or dermatophyto-
human innate immunity brought these so-called pattern recognition recep- sis. Moreover, little is known about immunity to most other fungal
tors (PRRs) to the attention of the entire
scientific community and Nobel prizes in
Medicine to scientists Jules Hoffman and
Bruce Beutler in 2011. Fungal recognition
by the innate immune system also led to the
discovery of another class of mammalian
PRRs, the C-type lectin receptors (CLR),
as well as the identification of new intra-
cellular signaling pathways modulated by
CLRs (49). It turns out that there are hun-
pathogens, especially emerging pathogens (such as the less-common A revealing example of the pervasive bottlenecks is the diagnosis of
filamentous fungi) and endemic diseases in developing countries such invasive aspergillosis, in which serum testing for fungal galactomannan is
as paracoccidioidomycosis. The potential role of fungal pathogens in about 80% sensitive for the detection of this disease in neutropenic pa-
the immune pathology of inflammatory and autoimmune diseases—for tients who are not taking itraconazole, voriconazole, and posaconazole—
example, Crohn’s disease, sarcoidosis, colitis (55), and arthritis—also re- a therapeutic regimen called antimould prophylaxis—but only about 20%
quires attention by scientists. sensitive if the patients are taking these drugs (57). This diagnostic measure
is even less efficient in intensive care or solid organ transplant patients
(58). Chronic pulmonary aspergillosis, on the other hand, is often con-
CLINICAL ARSENAL fused with tuberculosis both radiologically and clinically. Although the
diagnosis of chronic pulmonary aspergillosis is theoretically uncom-
One of the greatest challenges in the field is the shortcomings in current plicated, with detection of circulating anti-Aspergillus antibodies as a
techniques of diagnosing invasive fungal diseases (a typical clinical scenario main diagnostic tool, antibody detection itself is far from standardized,
is shown in Fig. 3). Culturing the organism is insensitive and slow; for with few commercial suppliers and a lack of consensus among clinicians
example, a blood culture has a sensitivity of ~50% for invasive candidiasis on performance characteristics. These complexities, combined with subtle
and 0% for invasive aspergillosis. Although the identification of some infec- clinical presentations, often result in delayed diagnosis and compromise
tions is relatively straightforward—such as the detection of cryptococcal clinical care. Robust and simple diagnostics along with better screening
Fig. 4. Paucity of targets and therapeutics. Representation of the fungal cell pinpointing the pathogen components targeted by the various
classes of antifungal drugs currently in clinical use. The structures of representative drugs are also shown. Adapted from (74) with permission.
CREDIT: C. BICKEL/SCIENCE TRANSLATIONAL MEDICINE
its the scope of drug discovery and development. The global antifungal eases could transform the current practice of antifungal prophylaxis and
drug market was worth $9.8 billion in 2009 (59). The structural classes empirical therapy as well as surveillance strategies.
and targets of antifungal agents currently in clinical use are illustrated The ideal solution would be to prevent fungal infection through vac-
in Fig. 4. The introduction of the echinocandins (the only new class of cination, but currently, there are no vaccines in clinical use for any fungal
drug licensed within the last 10 years) and the third-generation triazoles pathogen. Advances in our understanding of antifungal immunity have led
(voriconazole and posaconazole), in particular, has improved ther- to the development of several vaccines against a number of fungal patho-
apeutic options for many fungal diseases (60). Yet, antifungal drugs gens, and some have been shown to be effective in animal models (69).
have had modest success in reducing the high mortality rates associated However, few have been translated to clinical trials because of lack of
with invasive diseases. This is due, in large part, to the lack of early and funding and difficulties in conducting efficacy trials in an era in which
directed antifungal therapy caused by the delays in disease diagnosis the highest-risk individuals routinely receive antifungal prophylaxis (70).
and fungal identification. These drugs also suffer from restrictions in In addition, two formidable scientific challenges will need to be overcome
route of administration, spectrum of activity, and bioavailability in tar- if protective vaccines against the invasive mycoses are to become a reality.
get tissues (such as the brain) (61). First, many of the persons in high-risk vaccine target populations are im-
Further complications include toxicity, undesirable drug interac- munocompromised. Vaccination responses are diminished in these pa-
tions, and the emergence of drug resistance. For example, interactions tients, and the use of live vaccines is generally contraindicated. Second,
with statins, corticosteroids, and other drugs greatly limit the use of antigen-specific T cell responses are paramount to protecting against
SUPPLEMENTARY MATERIALS 23. F. C. Odds, M. F. Hanson, A. D. Davidson, M. D. Jacobsen, P. Wright, J. A. Whyte, N. A. Gow,
www.sciencetranslationalmedicine.org/cgi/content/full/4/165/165rv13/DC1 B. L. Jones, One year prospective survey of Candida bloodstream infections in Scotland.
Supplementary Materials J. Med. Microbiol. 56, 1066–1075 (2007).
24. U.S. & World Population Clocks; http://www.census.gov/main/www/popclock.html.
25. J. Morgan, Global trends in candidemia: Review of reports from 1995–2005. Curr. Infect.
REFERENCES AND NOTES Dis. Rep. 7, 429–439 (2005).
26. W. W. Hope, T. J. Walsh, D. W. Denning, The invasive and saprophytic syndromes due to
1. M. C. Fisher, D. A. Henk, C. J. Briggs, J. S. Brownstein, L. C. Madoff, S. L. McCraw, S. J. Gurr, Aspergillus spp. Med. Mycol. 43 (Suppl. 1), S207–S238 (2005).
Emerging fungal threats to animal, plant and ecosystem health. Nature 484, 186–194 27. J. Guinea, M. Torres-Narbona, P. Gijón, P. Muñoz, F. Pozo, T. Peláez, J. de Miguel, E. Bouza,
(2012). Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: Incidence,
2. B. Havlickova, V. A. Czaika, M. Friedrich, Epidemiological trends in skin mycoses worldwide. risk factors, and outcome. Clin. Microbiol. Infect. 16, 870–877 (2010).
Mycoses 51 (Suppl. 4), 2–15 (2008). 28. C. Garcia-Vidal, A. Upton, K. A. Kirby, K. A. Marr, Epidemiology of invasive mold infections in
3. J. Thomas, G. A. Jacobson, C. K. Narkowicz, G. M. Peterson, H. Burnet, C. Sharpe, Toenail allogeneic stem cell transplant recipients: Biological risk factors for infection according to
onychomycosis: An important global disease burden. J. Clin. Pharm. Ther. 35, 497–519 (2010). time after transplantation. Clin. Infect. Dis. 47, 1041–1050 (2008).
4. J. D. Sobel, Vulvovaginal candidosis. Lancet 369, 1961–1971 (2007). 29. D. W. Denning, A. Pleuvry, D. C. Cole, Global burden of allergic bronchopulmonary aspergillosis
5. M. Saccente, in Clinical Mycology, E. J. Anaissie, M. R. McGinnia, M. A. Pfaller, Eds. (Churchill with asthma and its complication chronic pulmonary aspergillosis in adults. Med. Mycol.,
Livingstone, London, UK, 2009), pp. 417–429. 10.3109/13693786.2012.738312 (2012).
6. World Health Organization, Tuberculosis; http://www.who.int/mediacentre/factsheets/ 30. H. S. Nam, K. Jeon, S. W. Um, G. Y. Suh, M. P. Chung, H. Kim, O. J. Kwon, W. J. Koh, Clinical
fs104/en/. characteristics and treatment outcomes of chronic necrotizing pulmonary aspergillosis: A
7. World Health Organization, Malaria; http://www.who.int/mediacentre/factsheets/fs094/en/. review of 43 cases. Int. J. Infect. Dis. 14, e479–e482 (2010).
53. L. Liu, S. Okada, X. F. Kong, A. Y. Kreins, S. Cypowyj, A. Abhyankar, J. Toubiana, Y. Itan, M. Audry, 73. P. G. Pappas, B. Bustamante, E. Ticona, R. J. Hamill, P. C. Johnson, A. Reboli, J. Aberg, R. Hasbun,
P. Nitschke, C. Masson, B. Toth, J. Flatot, M. Migaud, M. Chrabieh, T. Kochetkov, A. Bolze, H. H. Hsu, Recombinant interferon-g1b as adjunctive therapy for AIDS-related acute crypto-
A. Borghesi, A. Toulon, J. Hiller, S. Eyerich, K. Eyerich, V. Gulácsy, L. Chernyshova, V. Chernyshov, coccal meningitis. J. Infect. Dis. 189, 2185–2191 (2004).
A. Bondarenko, R. M. Grimaldo, L. Blancas-Galicia, I. M. Beas, J. Roesler, K. Magdorf, D. Engelhard, 74. F. C. Odds, A. J. Brown, N. A. Gow, Antifungal agents: Mechanisms of action. Trends Microbiol.
C. Thumerelle, P. R. Burgel, M. Hoernes, B. Drexel, R. Seger, T. Kusuma, A. F. Jansson, 11, 272–279 (2003).
J. Sawalle-Belohradsky, B. Belohradsky, E. Jouanguy, J. Bustamante, M. Bué, N. Karin, G. Wildbaum, 75. J. R. Rees, R. W. Pinner, R. A. Hajjeh, M. E. Brandt, A. L. Reingold, The epidemiological
C. Bodemer, O. Lortholary, A. Fischer, S. Blanche, S. Al-Muhsen, J. Reichenbach, M. Kobayashi, features of invasive mycotic infections in the San Francisco Bay area, 1992–1993: Results of
F. E. Rosales, C. T. Lozano, S. S. Kilic, M. Oleastro, A. Etzioni, C. Traidl-Hoffmann, E. D. Renner, population-based laboratory active surveillance. Clin. Infect. Dis. 27, 1138–1147 (1998).
L. Abel, C. Picard, L. Maródi, S. Boisson-Dupuis, A. Puel, J. L. Casanova, Gain-of-function 76. B. Spellberg, J. Edwards Jr., A. Ibrahim, Novel perspectives on mucormycosis: Patho-
human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous can- physiology, presentation, and management. Clin. Microbiol. Rev. 18, 556–569 (2005).
didiasis. J. Exp. Med. 208, 1635–1648 (2011). 77. Blastomycosis: http://www.rightdiagnosis.com/b/blastomycosis/prevalence.htm
54. F. L. van de Veerdonk, T. S. Plantinga, A. Hoischen, S. P. Smeekens, L. A. Joosten, C. Gilissen, 78. K. C. Meyer, E. J. McManus, D. G. Maki, Overwhelming pulmonary blastomycosis asso-
P. Arts, D. C. Rosentul, A. J. Carmichael, C. A. Smits-van der Graaf, B. J. Kullberg, J. W. van der Meer, ciated with the adult respiratory distress syndrome. N. Engl. J. Med. 329, 1231–1236
D. Lilic, J. A. Veltman, M. G. Netea, STAT1 mutations in autosomal dominant chronic mu- (1993).
cocutaneous candidiasis. N. Engl. J. Med. 365, 54–61 (2011). 79. P. G. Pappas, J. C. Pottage, W. G. Powderly, V. J. Fraser, C. W. Stratton, S. McKenzie, M. L. Tapper,
55. I. D. Iliev, V. A. Funari, K. D. Taylor, Q. Nguyen, C. N. Reyes, S. P. Strom, J. Brown, C. A. Becker, H. Chmel, F. C. Bonebrake, R. Blum, R. W. Shafer, C. King, W. E. Dismukes, Blastomycosis in
P. R. Fleshner, M. Dubinsky, J. I. Rotter, H. L. Wang, D. P. McGovern, G. D. Brown, D. M. Underhill, patients with the acquired immunodeficiency syndrome. Ann. Intern. Med. 116, 847–853 (1992).
Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence co- 80. P. G. Pappas, M. G. Threlkeld, G. D. Bedsole, K. O. Cleveland, M. S. Gelfand, W. E. Dismukes,
litis. Science 336, 1314–1317 (2012). Blastomycosis in immunocompromised patients. Medicine 72, 311–325 (1993).
56. J. N. Jarvis, A. Percival, S. Bauman, J. Pelfrey, G. Meintjes, G. N. Williams, N. Longley, T. S. Harrison, 81. Coccidioidomycosis: http://emedicine.medscape.com/article/215978-overview#a0156